SWOG clinical trial number

Randomized Phase II Trial Of Gemcitabine, Avelumab and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery For Cisplatin-Ineligible Muscle-Ineligible Urothelial Carcinoma: SWOG GAP TRIAL

Abbreviated Title
Status Notes
The study referenced above is closed to participant accrual effective November 15th, 2023, at 3:00 p.m. Eastern Time.

Research committees

Genitourinary Cancer


Carboplatin Gemcitabine hydrochloride Avelumab

Eligibility Criteria Expand/Collapse

5.1 Disease Related Criteria
a. Participants must have one of the following:
- histologically documented muscle-invasive bladder carcinoma (MIBC) from TURBT within 56 days prior to registration
- histologically confirmed high grade upper tract urothelial carcinoma (UTUC) within 56 days prior to registration, with invasion confirmed by either a mass on cross-sectional imaging or a tumor directly visualized during upper urinary tract endoscopy within 56 days prior to registration.

Participants diagnosed with mixed urothelial carcinoma and variant histology within 56 days prior to registration may be eligible if the majority (>50%) of the tumor consists of urothelial carcinoma. Participants with pure non-urothelial variant histologies or any small cell histology are not eligible.

b. Participants must have clinical stage T2-T4aN0M0 bladder or upper tract cancer confirmed by radiologic staging (CT scan/MRI abdomen and pelvis, and CT scan/x-ray of the chest) within 56 days prior to registration.
c. Participants must have a bone scan within 56 days prior to registration if they have bone pain or elevated serum alkaline phosphatase.
d. Participants must have a bimanual examination under anesthesia within 56 days prior to registration.
5.2 Prior/Concurrent Therapy Criteria
a. Participants must not have received prior systemic chemotherapy, immunotherapy or radiotherapy for the treatment of muscle invasive bladder cancer (MIBC) or upper tract urothelial carcinoma (UTUC). Other prior pelvic radiotherapy is allowed if it does not preclude surgery (radical cystectomy, nephroureterectomy or ureterectomy, based on location of primary tumor). Prior intravesical therapy is allowed.
b. Participants must not have received immunosuppressive medication within 14 days prior to registration, with the exception of intranasal, inhaled, topical steroids, or local steroid injections (e.g., intra-articular injection) systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent.
5.3 Clinical/Laboratory Criteri
a. Participants must be >= 18 years of age.
b. Participants must have Zubrod Performance Status 0-2 (see Section 10.4).
c. Participants must have history and physical examination within 28 days prior to registration.
d. Participants must be surgical candidates as deemed by the local site oncologic surgeon within 28 days prior to registration. This must be clearly documented.
e. Participants must have a serum creatinine <= the IULN OR measured OR calculated creatinine clearance >= 30 mL/min using the Cockroft-Gault Formula below. This specimen must have been drawn and processed within 28 days prior to registration:
Calculated Creatinine Clearance = (140 - age) x (weight in kg) / 72 x serum creatinine*
* Actual lab serum creatinine value with a minimum of 0.7 mg/dL.
f. Participants must be deemed cisplatin-ineligible based on greater than or equal to 1 of the following:
- Zubrod performance status=2
- creatinine clearance (calculated by Cockroft-Gault formula or measured) 30 to <60 ml/min,
- neuropathy >grade 1
- hearing loss >grade 1
- congestive heart failure >grade 2.
g. Participants must have adequate organ and marrow function as defined below within 28 days prior to registration:
-hemoglobin >= 9.0 g/dL
- absolute neutrophil count >= 1,500/mcL
-platelets >= 100,000/mcL
-total bilirubin <= 1.5 x institutional upper limit of normal (ULN)
-AST <= 2.5 x institutional ULN
-ALT <= 2.5 x institutional ULN

h. Participants with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, must have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification (see Appendix 18.1) and be class 2B or better.
i. Participant must not have any other prior malignancy except for the following: adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, prostate cancer Gleason score ≤ 3+4 in active surveillance, adequately treated Stage I or II cancer from which the participant is currently in complete remission, or any other cancer from which the participant has been disease free for two years.
j. Participants must not be pregnant or nursing due to the risk of harm to a fetus or nursing infant. Women/men of reproductive potential must have a negative serum or urine pregnancy test within 28 days prior to registration and must have agreed to use an effective contraceptive method. A woman is considered to be of "reproductive potential" if she has had menses at any time in the preceding 12 consecutive months. In addition to routine contraceptive methods, "effective contraception" also includes heterosexual celibacy and surgery intended to prevent pregnancy (or with a side-effect of pregnancy prevention) defined as a hysterectomy, bilateral oophorectomy or bilateral tubal ligation. However, if at any point a previously celibate participant chooses to become heterosexually active during the time period for use of contraceptive measures outlined in the protocol, he/she is responsible for beginning contraceptive measures.
k. Participants with known human immunodeficiency virus (HIV) must be on effective anti-retroviral therapy and have undetectable viral load at their most recent viral load test and within 6 months prior to registration.
l. Participants must not have a history of active primary immunodeficiency.
m. Participants must not have a history of or active autoimmune or inflammatory disorder, with the exception of vitiligo, alopecia, hypothyroidism (stable on hormone replacement), or chronic skin condition that does not require systemic therapy.
5.4 Specimen Submission Criteria
a. Participants must be offered the opportunity to participate in specimen banking as outlined in Section 15.1.
5.5 Regulatory Criteria
a. Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines.
NOTE: As a part of the OPEN registration process (see Section 13.2 for OPEN access instructions) the treating institution's identity is provided in order to ensure that the current (within 365 days) date of institutional review board approval for this study has been entered in the system.

Publication Information Expand/Collapse


Randomized Phase II Trial Of Gemcitabine, Avelumab and Carboplatin vs. No Neoadjuvant Therapy Preceding Surgery for Cisplatin-Ineligible Muscle-Invasive Urothelial Carcinoma (MIUC): SWOG Gap Trial (S2011)

G Sonpavde;M Plets;M Liss;J Meeks;D Petrylak;S Cole;R McKay;S Gupta;S Hita;T Pereira;R Bangs;C Tangen;IM Thompson;SP Lerner JCO Vol 40 Issue 6 Supp; ASCO Genitourinary (GU) Cancers Symposium 2022 (Feb 17-19, 2022, San Francisco, CA), poster


G Sonpavde;M Plets;M Liss;J Meeks;D Petrylak;S Cole;R McKay;S Gupta;T Pereira;R Bangs;C Tangen;IM Thompson;SP Lerner Society of Urologic Oncology (Nov 30, 2022 - Dec 02, 2022, San Diego, CA), poster

Other Clinical Trials

SWOG Clinical Trial Number

S2210, "Targeted Neoadjuvant Treatment for Patients with Localized Prostate Cancer and Germline DNA Repair Deficiency"

Research Committee(s)
Genitourinary Cancer
SWOG Clinical Trial Number
SWOG Clinical Trial Number